GOVX Stock Overview
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform.
+ 1 more risk
GeoVax Labs, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.79|
|52 Week High||US$4.58|
|52 Week Low||US$0.55|
|1 Month Change||-19.23%|
|3 Month Change||-34.26%|
|1 Year Change||-83.18%|
|3 Year Change||-96.97%|
|5 Year Change||-100.00%|
|Change since IPO||-100.00%|
Recent News & Updates
We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth CarefullySep 08
Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite RiskyMay 24
We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business GrowthNov 27
We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business GrowthAug 14
Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?Feb 18
|GOVX||US Biotechs||US Market|
Return vs Industry: GOVX underperformed the US Biotechs industry which returned -14.4% over the past year.
Return vs Market: GOVX underperformed the US Market which returned -18.5% over the past year.
|GOVX Average Weekly Movement||21.7%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: GOVX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: GOVX's weekly volatility has decreased from 33% to 22% over the past year, but is still higher than 75% of US stocks.
About the Company
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S.
GeoVax Labs, Inc. Fundamentals Summary
|GOVX fundamental statistics|
Is GOVX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GOVX income statement (TTM)|
|Cost of Revenue||US$18.25m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.85|
|Net Profit Margin||-9,079.68%|
How did GOVX perform over the long term?See historical performance and comparison